Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gantenerumab in early Alzheimer's disease
CTR20182180Phase 3Terminated
- Sponsor
- Roche
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of gantenerumab in Alzheimer's disease (AD), sponsored by Roche. Started Jul 2019; status: terminated.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20182180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182180.